Clinical Trials Directory

Trials / Completed

CompletedNCT01166932

Comparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumonia

COMPARISON OF CLINICAL EFFICACY OF COMBINATION Amoxycillin Plus Clavulanic Acid and Oxacillin Plus Ceftriaxone for HOSPITAL TREATMENT OF COMMUNITY Acquired PNEUMONIA IN CHILDREN : A Randomized Clinical Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
104 (actual)
Sponsor
UPECLIN HC FM Botucatu Unesp · Academic / Other
Sex
All
Age
2 Months – 5 Years
Healthy volunteers
Not accepted

Summary

Objective: To compare the clinical effectiveness and hospital costs, the initial empirical treatment, Oxacillin / Ceftriaxone and Amoxicillin / Clavulanate in children with Community Acquired Pneumonia (CAP) severe. Methods: Clinical prospective randomized study in children aged two months to five years of age with a diagnosis of severe CAP, according to criteria of World Health Organization (WHO), admitted to the Pediatrics Ward of the Hospital of the Medical School of Botucatu- UNESP. We excluded children with comorbid disorders (primary and secondary immunodeficiency) with acute or chronic kidney disease, referred patients receiving antibiotics proposal and history of allergy to antibiotics proposed. We included 104 children who were randomized into two groups to receive: Oxacillin / Ceftriaxone IV (GCO, n = 48) and Amoxicillin / Clavulanate IV (GAA, n = 56). Patients of the GAA, after clinical improvement, has been receiving the same oral antibiotic, and maintaining clinical stability, were discharged from hospital, the GOC received any IV treatment. The outcomes analyzed were time to clinical improvement (fever and tachypnea), duration of oxygen therapy, hospitalization time, need to expand the antimicrobial spectrum progression to pleural effusion / empyema (DP / E) and hospital costs. Treatment failure was determined by the need to expand the antimicrobial spectrum after 48 hours of hospitalization.

Detailed description

eligibility: Children aged two months to five years with diagnosis of severe community acquired pneumonia, requiring hospitalization. Outcomes measures: time to clinical improvement (respiratory rate and fever), duration of oxygen therapy, length of stay in the Division of Pediatrics, evolution with clinical complications, need for broadening the spectrum antimicrobials.

Conditions

Interventions

TypeNameDescription
DRUGAmoxycillin/clavulanic acid100mg/Kg/day/10 days.
DRUGceftriaxone/oxacillin75 mg/Kg/day/10 days.

Timeline

Start date
2005-04-01
Primary completion
2007-04-01
Completion
2009-04-01
First posted
2010-07-21
Last updated
2010-11-01

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT01166932. Inclusion in this directory is not an endorsement.